"What is Onglyza (saxagliptin)?
Onglyza (saxagliptin) is an oral drug approved in July of 2009 for the control of blood glucose in adults with type 2 diabetes.
Onglyza (saxagliptin) is a dipeptidyl peptidase-4 (DPP-4) inhib"...
- Patient Information:
Details with Side Effects
Overdosage of sulfonylureas, including Diaβeta, can produce hypoglycemia. Mild hypoglycemic symptoms without loss of consciousness or neurologic findings should be treated aggressively with oral glucose and adjustments in drug dosage and/or meal patterns. Close monitoring should continue until the physician is assured that the patient is out of danger. Severe hypoglycemic reactions with coma, seizure, or other neurological impairment occur infrequently, but constitute medical emergencies requiring immediate hospitalization. If hypoglycemic coma is diagnosed or suspected, the patient should be given a rapid intravenous injection of concentrated (50%) glucose solution. This should be followed by a continuous infusion of a more dilute (10%) glucose solution at a rate that will maintain the blood glucose at a level above 100 mg/dL. Patients should be closely monitored for a minimum of 24 to 48 hours, since hypoglycemia may recur after apparent clinical recovery.
Diaβeta is contraindicated in patients:
- With known hypersensitivity to the drug or any of its excipients.
- With type 1 diabetes mellitus or diabetic ketoacidosis, with or without coma. These conditions should be treated with insulin.
- Treated with bosentan.
Last reviewed on RxList: 11/18/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional DiaBeta Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.